Bill Mezzanotte

Money Moves

Leads the lixudebart development program for CSL

CSL will pay Alentis Therapeutics $355 million upfront to co-develop lixudebart, an antibody for rare kidney and liver diseases. Milestones could add $1.2 billion, with profits split 55% to CSL and 45% to Alentis, and CSL is funding every trial, which the Australian Financial Review puts at up to $2.2 billion in total.

Updated Oct 24